Literature DB >> 16724366

Therapies for psoriatic nail disease. A systematic review.

Sarah Cassell1, Arthur F Kavanaugh.   

Abstract

Nail involvement is common in patients with psoriasis and psoriatic arthritis, affecting 80%-90% of patients at some time. It also has significant effects on quality of life. Psoriatic nail disease can be refractory to treatment, and different features may respond variably to different therapies. The lack of standardized outcome assessments hinders the interpretation of available data. In this systematic evidence-based review of the literature, we assess various treatments for psoriatic nail disease.

Entities:  

Mesh:

Year:  2006        PMID: 16724366

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  16 in total

Review 1.  Treatment algorithms for early psoriatic arthritis: do they depend on disease phenotype?

Authors:  William Tillett; Neil McHugh
Journal:  Curr Rheumatol Rep       Date:  2012-08       Impact factor: 4.592

Review 2.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J Sieper; P Emery; E C Keystone; M H Schiff; P Mease; P L C M van Riel; R Fleischmann; M H Weisman; M E Weinblatt
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

Review 3.  The treatment of psoriatic arthritis and inflammatory spondylitis.

Authors:  Hernan Castro-Rueda; Arthur Kavanaugh
Journal:  Curr Pain Headache Rep       Date:  2008-12

4.  [Treatment recommendations for psoriatic arthritis].

Authors:  W-H Boehncke
Journal:  Z Rheumatol       Date:  2009-12       Impact factor: 1.372

5.  [Psoriatric arthritis - a permanent challenge for rheumatologists and patients: part 2: imaging diagnostics, classification and therapy].

Authors:  S Finzel; M Englbrecht
Journal:  Z Rheumatol       Date:  2011-11       Impact factor: 1.372

6.  Efalizumab in the Treatment of Scalp, Palmoplantar and Nail Psoriasis: Results of a 24-Week Latin American Study.

Authors:  María Denise Takahashi; Edgardo Néstor Chouela; Gladys Leon Dorantes; Ana Maria Roselino; Jesùs Santamaria; Miguel Angel Allevato; Tania Cestari; Maria Eugenia Manzanera de Aillaud; Fernando Miguel Stengel; Daiana Licu
Journal:  Arch Drug Inf       Date:  2010-03

7.  Nail psoriasis: clinical presentation and best practice recommendations.

Authors:  Felicity Edwards; David de Berker
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 8.  Psoriatic arthritis: pharmacotherapy update.

Authors:  Philip J Mease
Journal:  Curr Rheumatol Rep       Date:  2010-08       Impact factor: 4.592

Review 9.  Treatment recommendations for psoriatic arthritis.

Authors:  C T Ritchlin; A Kavanaugh; D D Gladman; P J Mease; P Helliwell; W-H Boehncke; K de Vlam; D Fiorentino; O Fitzgerald; A B Gottlieb; N J McHugh; P Nash; A A Qureshi; E R Soriano; W J Taylor
Journal:  Ann Rheum Dis       Date:  2008-10-24       Impact factor: 19.103

10.  Assessing the Impact of Efalizumab on Nail, Scalp and Palmoplantar Psoriasis and on Quality of Life: Results from a Multicentre, Open-label, Phase IIIb/IV Trial.

Authors:  Andreas Katsambas; Ketty Peris; Gino Vena; Peter Freidmann; Gottfried Wozel; Esteban Daudén; Daiana Licu; Mauro Placchi; Michel De La Brassinne
Journal:  Arch Drug Inf       Date:  2009-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.